Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04213885 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position
A Phase 2 study of Keratoconus, Unstable and Bacterial Keratitis, sponsored by Eye Specialists of Indiana.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04213885 is a Phase 2 study of Keratoconus, Unstable and Bacterial Keratitis that has completed, run by Eye Specialists of Indiana. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04213885, a Phase 2 study of Keratoconus, Unstable and Bacterial Keratitis, has completed, sponsored by Eye Specialists of Indiana.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal thinning conditions.
Conditions Studied
Interventions
- COMBINATION_PRODUCT PXL 330 Platinum device/Riboflavin
Study Locations (1)
Indiana
- Eye Specialists of Indiana - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-05-04 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04213885
The ClinicalTrials.gov registry entry for NCT04213885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eye Specialists of Indiana, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Keratoconus, Unstable appearing as the primary indexed condition, and to 1 intervention - of which PXL 330 Platinum device/Riboflavin is the first listed.
NCT04213885 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04213885 about?
NCT04213885 is a clinical study titled "Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position". To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal thinning conditions.
What is the current status of trial NCT04213885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-05-04. Estimated completion is 2024-08-05.
What conditions does trial NCT04213885 study?
This clinical trial studies the following conditions: Keratoconus, Unstable, Bacterial Keratitis, Ectasia Corneal.
What interventions are being tested in trial NCT04213885?
The interventions under investigation include: PXL 330 Platinum device/Riboflavin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04213885?
This trial is sponsored by Eye Specialists of Indiana, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04213885 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus, Unstable
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.